Sean Lee
Stock Analyst at HC Wainwright & Co.
(3.50)
# 932
Out of 4,712 analysts
67
Total ratings
33.82%
Success rate
10.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Reiterates: Buy | $7 | $3.71 | +88.68% | 12 | Dec 19, 2024 | |
| PSTV Plus Therapeutics | Reiterates: Buy | $8 | $1.16 | +589.66% | 10 | Nov 26, 2024 | |
| MYO Myomo | Reiterates: Buy | $7.5 | $6.37 | +17.74% | 4 | Nov 13, 2024 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $6 → $22 | $24.53 | -10.31% | 8 | Nov 11, 2024 | |
| CTSO Cytosorbents | Reiterates: Neutral | $1 | $0.94 | +6.39% | 11 | Nov 11, 2024 | |
| ATEC Alphatec Holdings | Reiterates: Buy | $20 | $9.19 | +117.63% | 10 | Oct 31, 2024 | |
| KZIA Kazia Therapeutics | Reiterates: Buy | $20 | $3.07 | +551.47% | 4 | Jul 12, 2024 | |
| CASI CASI Pharmaceuticals | Maintains: Buy | $12 → $6 | $2.98 | +101.34% | 7 | May 15, 2024 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $30 | $0.97 | +2,998.53% | 1 | Dec 5, 2022 |
Verastem
Dec 19, 2024
Reiterates: Buy
Price Target: $7
Current: $3.71
Upside: +88.68%
Plus Therapeutics
Nov 26, 2024
Reiterates: Buy
Price Target: $8
Current: $1.16
Upside: +589.66%
Myomo
Nov 13, 2024
Reiterates: Buy
Price Target: $7.5
Current: $6.37
Upside: +17.74%
Monopar Therapeutics
Nov 11, 2024
Maintains: Buy
Price Target: $6 → $22
Current: $24.53
Upside: -10.31%
Cytosorbents
Nov 11, 2024
Reiterates: Neutral
Price Target: $1
Current: $0.94
Upside: +6.39%
Alphatec Holdings
Oct 31, 2024
Reiterates: Buy
Price Target: $20
Current: $9.19
Upside: +117.63%
Kazia Therapeutics
Jul 12, 2024
Reiterates: Buy
Price Target: $20
Current: $3.07
Upside: +551.47%
CASI Pharmaceuticals
May 15, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $2.98
Upside: +101.34%
Akari Therapeutics,
Dec 5, 2022
Initiates: Buy
Price Target: $30
Current: $0.97
Upside: +2,998.53%